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ABSTRACT 
Objective: The study was aimed to investigate the cytotoxic effect of S-5H-[1,2,4]-triazino (5,6-b) indol-3-yl-3,4-phenylethane-thioate derivatives as 
epidermal growth factor Receptor (EGFR) inhibitors.  
Methods: In the present study 14 novel triazine analogues were synthesized and characterized using different spectroscopic techniques such as FT-
IR, NMR and Mass Spectroscopy. The anticancer activity was performed using MCF-7 (breast cancer) and K-562 (leukaemia) cell lines. Further, 
molecular docking was carried out using Vlife Molecular Docking Software (MDS) on crystal structure of epidermal growth factor receptor (EGFR) 
to identify the binding mode of interaction with an active site.  
Results: Compounds MA-7, MA-8, MA-12, MA-13 and MA-14 show potent activity against cancer cell lines in the range of<10 to 84.4 µg/ml. Further 
molecular docking on EGFR also supports that there is a strong correlation between in silico and in vitro biological activity. The results of this study 
may be further useful for lead optimization process.  
Conclusion: The results of this study indicates that the synthesized triazine analogues can give a potential lead as an anticancer agent.  
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INTRODUCTION 
Cancer is a condition that refers to a state in which the cell present 
in the body gone awry and reproduced in an uncontrollable manner 
[1]. The healthy tissues and organs that are present in the body are 
then proliferated or intrude get destroyed [2]. The growth of the 
cancer begins with one part/specific organ of the body and further 
spread into the entire body. Cancerous cells segregate and mimic 
themselves and could be present in the form of a cluster of infected 
cells that are known as malignancy (tumor) [3]. The symptom of 
cancer originated from the coercing, pulverizing and destroying the 
surrounding healthy cells and tissues [4]. The immune system has 
crucial role in the management and elimination of early cancer or 
premalignant cells because the immune system is associated with 
increased incidences of a variety of cancer [5]. In women, breast 
cancer is a more common while, colorectal, prostate and lung cancer 
occurs most commonly in men [6]. Development of breast cancer is 
seen most commonly in the cells present in the inner linings of the 
milk ducts and the lobules, which are the major source for the 
supply of the milk in the ducts [7]. Factors emerging risk of breast 
cancer are obesity, decrease in physical exertion, alcohol intake, 
hormone replacement therapy at the ongoing menopause, early age 
menstruation, late pregnancy or no pregnancy at all. Approximately 
5% of cases are occurring due to the inherited gene expression from 
the patient’s parents. Risk factors for cancer also involve breast 
cancer genes namely BRCA-1 and BRCA-2 among others [8]. The 
other type of cancer we have focused is leukaemia which is known 
as blood cancer and starts with the bone marrow and results into the 
multiplication of white blood cells (WBCs) [9]. With the progression 
of leukaemia, the infected cells crowed out to suppress the growth of 
normal cells. Sometimes some hairy thin projections are seen in an 
infrequent chronic leukaemia which is called as hairy cell leukaemia 
(HCL) that starts with the bone marrow and the accumulation of 
these hairy cells present in the bone marrow, liver and spleen. 
Though hairy cell leukaemia strikes the WBC, the enlargement in the 
lymph nodes doesn’t observed [10]. Although there are no clear 
symptoms for the development of HCL in the early stage. 
EGFR receptor is devided in to four receptors namely EGFR (ErbB-
I/HER-1{Human Epidermal Growth Factor Receptor-1}) ErbB-II 
(Neu, HER-2), ErbB-III (HER-3) and ErbB-IV (HER-4) [11]. RTK 
family contains an extracellular ligand-binding domain that is a 
hydrophobic transmembrane domain, and cytoplasmic tyrosine 
kinase domain [12]. A knockout model for EGFR shows the lethality 
of embryo and defects in tissues or organs. The abnormal activation 
of EGFR is expressed in many types of specific diseases [13]. The 
pleiotropic function of EGFR signaling helps to develop and regulate 
various physiological functions of the body [14]. The incrimination 
of various types of disorders has been defined by the exponential 
expression of EGFR. There are several reports are available in the 
literature suggesting that aromatic and heteroaromatic substitution 
over chosen triazine ring moiety shows potent anticancer activity, 
therefore, here in this study the substituted benzoic acids were used 
and were studied as anticancer agents [15]. The main objective of 
the study is to perform synthesis and anticancer screening of 
synthesized compounds using various cell lines.  
MATERIALS AND METHODS 
Chemicals and reagents 
Raw materials were purchased from Loba Chemie, Sigma Aldrich, 
Merck (India), Sisco Research Laboratory SRL (India) and 
Spectrochem Pvt. Ltd. and were of the synthetic grade. Melting point 
detection was conducted by using Veego VMP-D digital apparatus. 
Silica gel precoated F-254 TLC plates were used for monitoring the 
progress of reaction; further detection of the retention factor is 
obtained by either staining by iodine or visualizing under UV-light 
chamber. Fourier transform infrared (FT-IR) spectra were obtained 
by making sample cuvettes in anhydrous potassium bromide (KBr) 
on “JASCO FTIR 4100” and are reported in cm-1. 1H-NMR spectra 
were illustrated on “Bruker Avance having a frequency of 400 MHz 
using DMSO-D6 in the presence of an internal standard 
tetramethylsilane (TMS). 
Step I: General procedure of synthesis of 1, 2, 4-triazino-(5, 6-
b)-indole-3-thione 
To a mixture of Isatin (0.01 mol) and thiosemicarbazide (0.01 mol), 
distilled water (300 ml) containing potassium carbonate (0.04 mol) 
was taken in a round bottom flask. The reaction flask was refluxed 
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for 4 h during which an initial intense red coloured solution turned 
orange. Upon cooling at room temperature, the reaction mixture was 
filtered and the residual filtrate obtained was acidified with glacial 
acetic acid to precipitate the yellow coloured product. Precipitates 
obtained by filtration were 3 to 4 times with water to obtain the 
crude product. The crude product was then stirred with methanol 
(25 ml) for 2 h, filtered, dried and subsequently re-crystallized to 
furnish the final product (1.34 g, 66.3%) [16]. 
  
Scheme of synthesis 
 
Step I 
 
 
Step II 
  
Step II General procedure of synthesis of S-5H-[1, 2, 4]-triazino-
(5,6-b)indol-3-yl-3,4-biphenylethanethioate (MA-1 to MA-14) 
Substituted benzoic acid (0.01 mol) and 1-Ethyl-3-(3-dimethyl-
aminopropyl) carbodiimide (EDC. HCl) was taken in 100 ml round 
bottom flask containing N-N dimethylformamide (DMF) as a solvent and 
the reaction mixture was then agitated for 2 h at 0 °C. Later, on the 
completion of 2 h the crude product (reaction step I (1)) was added (0.01 
mol). The reaction mixture was then agitated at room temperature for 
24 h. The reaction mixture was extracted with ethyl acetate (EtOAc), was 
filtered, dried and recrystallized with chloroform. 
Molecular docking studies 
Ligand preparation  
4-biphenylethanethioate derivatives were drawn as the template for 
building the compounds present in the dataset of V-Life molecular 
docking software (MDS) version 3.5. The geometry of the ligands 
was modified by the minimization of energy with the use of Merck 
Molecular force field (MMFF94) and charges for atoms was applied 
until a 0.001 kcal/mol/Å gradient was reached, perpetuating the 
rigid structure template throughout the process of minimization of 
energy [17]. 
Grid generation 
Using the Vlife molecular docking software (MDS) version 3.5 the grid 
map was centralized at the active site of the protein.  
The grid map was streamlined at the residues namely ASP 212 (A), 
LYS 179 (A), HIS 180(A), ARG 174(A), ASP 269(A), HIS 268 (A), 
TYR59(A), GLN 63 (A), ASP 273 (A) respectively which were then 
forecasted from the ligpot. 
Docking file generation 
On the activation of the receptor EGFR (1M17) signalling pathways 
are strongly activated for anticancer activity. Hence, EGFR-1M17 
was selected as a biological target for the docking study. The 
crystallized structure was retrieved from the Protein Data Bank 
(PDB) {www. rcsb. org/pdb}. The receptor was optimized; saved as. 
mol file and used for docking simulation. Two dimensional 
structures of the synthesized compounds were drawn and then 
transfigured into the 3D structures with Vlife MDS. Energy 
minimization of the 3D structures was performed up to the rms 
gradient of value 0.01 by the use of MMFF94. For all the conformers, 
energy minimization method was performed. The selection of the 
active site was done by picking the hollow having the utmost 
hydrophobic surface area of the receptor. The GA docking method 
was selected for the docking simulation. The virtual docking for all 
the conformers was conducted at elucidated cavity of the receptor. 
The fixed parameters of the docking simulation were the number of 
placements: 30, rotation angles 30 ° comprehensive method, scoring 
task: docking score. The rotation of the analogs to the divergent 
postures was obtained by the rotation angle. Besides docking 
simulation, the premier docked conformers of each ligand and 
receptor was transpired and assembled by elucidating the results of 
4Å. After optimization, complexes were examined for assorted 
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interSactions of the ligand with the receptor such as hydrogen 
bonding, hydrophobic bonding and van der Waal’s interaction [18]. 
In vitro anticancer evaluation 
The cell lines were grown on Roswell Park Memorial Institute 1640 
(RPMI0-1640) media that contains fetal bovine serum (10%) and L-
glutamine (2 mmol). Ninety-six well microtiter plates in 100 µl at the 
solidity of plates were used to inoculate the cells depending upon 
the multiplication time of cell lines. After the cell inoculation 
process, microtiter plates were incubated for 24h, the conditions 
were sustained as 37 °C, 5% CO2, 95% air and 100% Relative 
Humidity (Rh) before addition of synthesized compounds. The stock 
solution of the synthesized analogs was prepared at 100 mg/kg and was 
further diluted to 1 mg/ml with water and kept in chilled condition 
before use. Further, one fraction of chilled concentrate (1 mg/ml) was 
liquefied and was attenuated to 100, 200, 400 and 800 µg/ml 
respectively with whole media comprising of standard drug. A portion of 
10µg of dilutions containing diverse drugs was added to the suitable 
wells previously having 90 µl media resulting in the ultimate drug 
concentrations that are 10, 20, 40 and 80µg/ml respectively. 
After the addition of the compounds, plates were incubated in the 
standard conditions for 48h and assay was discontinued after 
inclusion of trichloroacetic acid (TCA). An in-situ condition was 
maintained with mixing 50 µl of chilled TCA gently (10% of TCA) 
followed by further incubation for 1h at the temperature of 4 °C. 
Removal of resilient liquid was discarded; plates were washed with 
water 4-6 times and were dried under air. Sulforhodamine B (SRB) 
solution at the concentrations of 50 µl at 0.4 % (w/v) in 1% acetic 
acid was appended to every well; 20 min. the incubation period of 
these plates was obtained at room temperature. Once the dying 
process is completed the portion of unbound dye was recuperated 
and the unconsumed dye was omitted by washing 4-5 times with 
acetic acid in the concentration of 1 % acetic acid. The plates were 
dried under the influence of air. Calculation of the percentage 
growth in plate sequence was compared to reference wells. Percent 
development of cells was revealed in terms of the proportion (ratio) 
of the mean absorbance of the well to the mean absorbance of the 
reference well X 100. By applying measurements of 6 absorbance 
[time 0], control growth (C), and the test in the presence of 4 
concentration extents (Ti)], the % growth was calculated at the 
concentration extent of every single drug [19-20]. 
  ∗ 100% 
In silico ADMET study 
For the identification and optimization of lead generation, in silico 
ADMET (absorption, distribution, metabolism, excretion, and 
toxicity) properties plays an essential role; ADMET SAR is open 
source software available online and was employed to predict the 
ADMET parameters. Here, the ADMET profile is estimated for the 
different analogs using the online server (www. lmmd. ecust. edu. cn, 
accessed on 5th March 2017) [20-21]. 
RESULTS AND DISCUSSION 
Characterization study 
Fourteen triazine derivatives MA-1 to MA-14 were synthesized. The 
yield of final compounds were obtained in the range of 50.00% to 
90.04%. Recrystallization was performed using ethanol. Structural 
characterization of synthesized analogues was done by IR, 1H-NMR 
and mass spectroscopy. The results of IR spectra confirm that all the 
compounds shows stretching under respective frequency within the 
range i. e; C-C Stretch (1500-1400 cm-1), C-N Stretch (1250-1335 cm-
1), S-C=O (1668-1705 cm-1) etc. 1H NMR spectra shows that protons 
of S-5H-[1,2.4]triazino[5,6-b]indol-3 were observed in the aromatic 
region under the range of 6.8-7.2 δ ppm. Further, Mass spectra of 
compounds also confirms synthesized compounds.  
S-5H-[1,2,4]-triazino (5,6-b) indol-3-yl-3, 4-biphenyl-
ethanethioate (MA-1) 
Molecular formula; C24H20N4OS (396.10), MP: 118-120ᵒC; yield 
74.04%; Rf = 0.69 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1297, 
1665, 3069, 3305; 1H-NMR (δ ppm; CDCl3): 2.30 (s, 3H,-CH3), 4.27 (s, 
2H,-CH2), 6.87-7.31 (m, 8H, biphenyl), 7.31-7.69 (m, 3H,-Ar). 
S-5H-[1,2,4]-triazino(5,6-b)indol-3-yl 2,4-dichlorobenzothioate 
(MA-2) 
Molecular formula: C16H8Cl2N4OS (373.98); MP: 275 °C; yield: 80%; 
Rf: 0.77 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1475.28, 
1308.46, 1700.91, 599.62; 1H-NMR (δ ppm; DMSO): 7.38-7.85 (m, 
3H,-Ar), 7.00-7.80 (m, 4H phenyl), ESI-MS: m/z 374.19 (M+H)+. 
S-5H-[1, 2, 4]triazino[5,6-b]indol-3-yl 3-bromobenzothioate (MA-3) 
Molecular formula: C16H9BrN4OS (385.24); MP: 276 °C; yield: 77%; 
Rf: 0.68 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1479.81, 
1311.36, 1698.34, 617.10; 1H-NMR (δ ppm; DMSO): 7.38-7.91 
(m,4H,-Ar), 7.00-7.55 (m, 4H phenyl) ESI-MS: m/z 384.8 (M-H)+.  
S-5H-[1,2,4]triazino[5,6-b]indol-3-yl 4-chlorobenzothioate (MA-4) 
Molecular formula: C16H9ClN4OS (340.79); MP: 277 °C; yield: 88%; 
Rf: 0.55(toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1478.33, 
1312.06, 1698.34, 619.10; 1H-NMR (δ ppm; DMSO): 7.36-8.00 (m, 
4H,-Ar), 7.05-7.43 (m, 5H phenyl) ESI-MS: m/z 340.02 (M+H)+. 
S-5H-[1,2,4]triazino[5,6-b]indol-3-yl benzothioate (MA-5) 
Molecular formula: C17H12N4OS (306.6); MP: >300 °C; yield: 77%; Rf = 
0.55(toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr):1475.28, 1306.46, 
1700.91, 599.62; 1H-NMR (δ ppm; DMSO): 7.0-7.55 (m, 4H,-Indole), 
7.5-7.97 (m, 5H,-Ar); m/z = 321.08 (M+H)+ 
S-5H-[1,2,4]triazino [5,6-b] indol-3-yl 4-methylbenzothioate (MA-6) 
Molecular formula: C17H12N4OS (320.37); MP: >300 °C; yield: 90%; Rf 
= 0.58(toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1500.35, 
1281.47, 1714.41, 2988.05; 1H-NMR (δ ppm; DMSO): 2.35 (s,-CH3), 
7.33-7.75 (m,-Ar), 7.00-7.85 (m, indole). 
S-5H-[1,2,4]triazino [5,6-b] indol-3-yl 3-methylbenzothioate (MA-7) 
Molecular formula: C17H12N4OS (320.37); MP: >300 °C; yield: 70%; 
Rf: 0.62(toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1431.69, 
1347.03, 1714.41, 2891.91, 1H-NMR (δ ppm; DMSO): 2.51 (s,-CH3), 
7.25-7.85 (m,-Ar), 7.06-7.88 (m, indole). 
S-5H-[1,2,4]triazino [5, 6-b] indol-3-yl 3,4,5-trihydroxybenzo-
thioate (MA-8) 
Molecular formula: C16H10N4O4S (354.34); MP: >300 °C; yield: 70%; 
Rf: 0.56 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1474.31, 
1310.39, 1696.91, 3115.44, 1H-NMR (δ ppm; DMSO): 5.0 (m,-OH), 
7.05-7.40 (m,-Ar), 7.0-7.85 (m, indole). 
S-5H-[1, 2, 4]triazino[5,6-b]indol-3-yl 3-methoxybenzothioate 
(MA-9) 
Molecular formula: C16H10N4O4S (336.37); MP: >300 °C; yield: 70%; 
Rf: 0.56 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1477.21, 
1300.36, 1686.88, 3120.422, 1H-NMR (δ ppm; DMSO): 5.0 (m,-OH), 
7.05-7.40 (m,-Ar), 7.0-7.85 (m, indole). 
S-5H-[1,2,4]triazino[5,6-b]indol-3-yl pyridine-3-carbothioate 
(MA-10) 
Molecular formula: C15H9N5OS (307.04); MP: >300 °C; yield: 88%; Rf: 
0.68 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1475.28, 1306.46, 
1700.91, 1H-NMR (δ ppm; DMSO): 7.00-7.85 (m, 4H, indole), 7.49-
7.64 (m,-Ar). 
S-5H-[1,2,4]triazino[5,6-b]indol-3-yl 3-aminobenzothioate (MA-
11) 
Molecular formula: C16H11N5OS (321.37); MP: >300 °C; yield: 90%; 
Rf: 0.68 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1499.05, 
1384.43, 1718.15, 1600.65; 1H-NMR (δ ppm; DMSO): 7.06-7.89 (m, 
4H, indole), 7.43-7.68 (m,-Ar) 4.32 (s, aromatic-NH). 
S-5H-[1,2,4]triazino[5,6-b]indol-3-yl 5-aminobenzothioate (MA-12) 
Molecular formula: C16H11N5OS (321.07); MP: >300 °C; yield: 93%; 
Rf: 0.68 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1500.35, 
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1381.28, 1714.41, 1599.66; 1H-NMR (δ ppm; DMSO): 7.00-7.85(m, 
4H, indole), 7.49-7.64 (m,-Ar) 4.0 (s, aromatic-NH). 
S-5H-[1,2,4]triazino[5,6-b]indol-3-yl 2-hydroxybenzthioate (MA-13) 
Molecular formula: C16H10N4O2S (322.35); MP: >300 °C; yield: 83%; 
Rf: 0.50 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1459.85, 
1297.86, 1699.34, 3233.88; 1H-NMR (δ ppm; DMSO): 7.00-7.85(m, 
4H, indole), 6.92-7.48 (m,-Ar), 5.0 (s, Ar-OH). 
S-5H-[1,2.4]triazino[5,6-b]indol-3-yl 3-nitrobenzthioate (MA-14) 
Molecular formula: C16H10N4O2S (322.35); MP: >300 °C; yield: 83%; 
Rf: 0.50 (toluene: EtOAc {4:1}); IR vmax (cm-1) (KBr): 1259.29, 
1468.53, 1699.94; 1H-NMR (δ ppm; DMSO): 7.00-7.85(m, 4H, indole), 
6.92-7.48 (m,-Ar). 
Molecular docking 
To investigate the interaction between epidermal growth factor 
receptor (EGFR) and synthesized derivatives; molecular docking 
study was carried out. Active compound MA-8 binds with ASP813A 
and VAL741A; MA-12 binds with ASP8134A, HIS811A and PHE832A; 
MA-13 binds with ASP8134A and PHE832A; MA-14 binds with 
ASP813A and LYS721A amino acids. Interaction of compounds with 
the crystal structure of epidermal growth factor receptor (EGFR) is 
shown in the fig. 1. 
 
 
Fig. 1: Docking interaction of compounds with 1M17 
 
 
Fig. 2: Phase contrast images of MCF-7 cells showing morphological changes following the treatment with synthesized compounds 
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Fig. 3: Phase contrast images of K-562 cells showing morphological changes following the treatment with synthesized compounds 
 
 
Fig. 4: Growth Curve: Human Breast Cancer Cell Line (MCF-7) 
 
 
Fig. 5: Growth Curve: Human Leukaemia Cell Line (K-562) 
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Table 1: Cytotoxicity on human breast cancer cell line MCF-7 
Human breast cancer cell line MCF-7 
% Control growth 
Drug concentrations (µg/ml) 
Compound 
code 
Experiment No. 1 Experiment No. 1 Experiment No. 1 Average values 
 10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
MA-1 80.4 79.0 64.1 58.4 75.3 76.4 69.5 53.0 91.6 91.0 27.8 30.1 82.5 82.1 53.8 47.2 
MA-2 87.7 86.8 75.0 65.4 82.8 83.5 72.4 62.2 93.1 82.6 58.8 57.3 87.9 84.3 68.7 61.7 
MA-3 80.5 73.3 56.3 40.2 80.8 75.4 55.4 42.4 95.2 95.6 84.6 98.7 85.5 81.4 65.4 60.4 
MA-4 45.9 6.9 1.4 7.6 39.7 7.7 2.9 11.2 105.5 110.9 94.8 75.9 63.7 41.8 33.0 31.5 
MA-5 75.8 79.7 74.0 72.7 78.2 79.1 70.6 68.7 116.3 114.2 109.2 103.5 90.1 91.0 84.6 81.6 
MA-6 76.6 77.3 81.0 79.8 76.7 80.8 81.3 78.5 101.5 103.2 107.4 87.1 84.9 87.1 89.9 81.8 
MA-7 86.9 81.8 71.2 58.3 77.7 79.2 73.2 60.4 53.1 67.3 49.7 34.9 72.6 76.1 64.7 51.2 
MA-8 78.2 68.4 8.8 11.8 80.8 76.9 14.2 11.8 79.2 64.9 33.8 26.7 79.4 70.1 18.9 16.7 
MA-9 69.7 56.4 37.8 34.6 72.7 61.9 41.8 39.9 79.0 62.7 31.6 23.4 73.8 60.3 37.1 32.7 
MA-10 77.0 71.0 67.3 86.0 79.7 74.2 73.8 89.4 75.5 62.6 35.4 28.2 77.4 69.3 58.8 67.9 
MA-11 87.2 81.4 74.5 65.6 88.0 84.9 77.9 72.0 98.8 102.8 93.1 109.7 91.3 89.7 81.8 82.4 
MA-12 92.4 91.2 78.5 83.2 95.0 89.1 80.0 92.2 -46.3 -48.3 -49.3 -15.2 47.0 44.0 36.4 53.4 
MA-13 85.3 93.9 91.8 72.9 92.2 90.8 88.0 88.5 -46.3 -46.5 -53.2 -10.5 43.8 46.1 42.2 50.3 
MA-14 89.3 75.5 53.4 42.0 89.6 86.1 69.2 57.7 -46.5 -29.1 -56.0 -18.4 44.1 44.2 22.2 27.1 
Adriamycin -
43.4 
-47.3 -50.2 -33.7 -43.4 -47.3 -50.2 -33.7 -43.4 -47.3 -50.2 -33.7 -43.4 -47.3 -50.2 -33.7 
 
Table 2: Cytotoxicity on human breast cancer cell line K-562 
Human breast cancer cell line K-562 
% Control growth 
Drug concentrations (µg/ml) 
Compound 
code 
Experiment No. 1 Experiment No. 1 Experiment No. 1 Average values 
 10 20 40 80 10 20 40 80 10 20 40 80 10 20 40 80 
MA-1 91.8 96.3 96.1 91.7 100.9 100.4 99.2 99.0 98.3 98.7 101.9 89.5 97.0 98.4 99.0 93.4 
MA-2 98.6 98.3 102.0 89.5 94.7 101.6 100.7 97.9 101.9 99.7 104.0 89.9 98.4 99.9 102.2 92.5 
MA-3 98.2 97.3 95.0 47.6 101.6 99.2 96.9 67.8 96.9 98.0 101.8 65.5 98.9 98.2 97.9 60.3 
MA-4 83.8 8.1 9.8 13.5 91.5 7.1 0.4 9.2 92.4 15.0 18.4 12.0 89.2 10.0 9.5 11.6 
MA-5 91.7 96.5 95.8 85.0 100.0 100.5 95.4 99.6 98.4 100.9 103.2 96.7 96.7 99.3 98.1 93.8 
MA-6 90.9 96.6 91.7 72.2 96.1 98.0 93.7 99.9 98.0 101.8 100.0 99.5 95.0 98.8 95.1 90.5 
MA-7 92.6 94.2 92.5 87.6 96.4 98.2 96.3 98.2 88.0 99.1 104.2 97.5 92.3 97.2 97.7 94.4 
MA-8 84.7 86.8 67.0 22.6 101.9 95.5 61.8 13.0 103.1 96.2 59.1 -10.2 96.6 92.9 62.6 8.5 
MA-9 96.5 82.7 105.7 95.9 102.7 98.6 102.1 89.8 103.9 101.6 111.1 83.9 101.0 94.3 106.3 89.9 
MA-10 96.7 73.4 96.8 84.8 102.1 96.6 82.1 84.2 108.6 88.5 87.5 32.0 102.4 86.2 88.8 67.0 
MA-11 94.5 99.3 105.5 92.8 103.5 97.3 99.6 95.4 106.9 101.4 107.0 90.3 101.6 99.3 104.0 92.8 
MA-12 98.4 96.7 101.2 97.7 100.0 101.2 99.5 99.1 103.8 106.4 103.9 100.9 100.7 101.4 101.5 99.2 
MA-13 97.2 93.1 99.7 83.3 99.1 101.9 98.7 92.5 103.8 103.0 98.8 81.5 100.0 99.3 99.1 85.8 
MA-14 90.5 82.8 69.0 28.3 97.1 96.5 82.4 47.1 94.4 82.5 67.9 27.1 94.0 87.3 73.1 34.1 
Adriamycin 12.4 7.5 -20.5 -
30.8 
7.5 6.4 -29.0 -
26.0 
13.6 13.5 -24.2 -34.0 11.2 9.1 -24.6 -
30.3 
 
Table 3: GI50 values (µg/ml) of standard and test compounds 
S. No. Compound code Growth inhibition 50% (GI50) values (µg/ml) 
MCF-7 K-562 
1. MA-1 67.6 >80 
2. MA-2 NE >80 
3. MA-3 NE >80 
4. MA-4 17.2 10.4 
5. MA-5 NE >80 
6. MA-6 NE >80 
7. MA-7 84.4 NE 
8. MA-8 33.5 49.1 
9. MA-9 39.3 >80 
10. MA-10 >80 >80 
11. MA-11 >80 >80 
12. MA-12 <10 >80 
13. MA-13 <10 63.2 
14. MA-14 <10 72.3 
STD Adriamycin <10 <10 
 
In vitro anticancer evaluation 
The newly synthesized conjugates bearing various substituents on 
the triazine ring were screened for their cytotoxicity on two cell 
lines namely breast cancer (MCF-7) and leukaemia (K-562) cell 
lines using SRB assay; Adriamycin was used as the positive 
control. The results of cytotoxic activity against cell lines are 
represented in table 1and table 2. GI50 values for standard and test 
compounds are depicted in the table 3. Compounds MA-12 (GI50 
=<10 µg/ml), MA-13 (GI50 =<10 µg/ml) and MA-14 (GI50 =<10 
µg/ml) were found to be the most active compounds against the 
breast cancer cell line and compound MA-4 (GI50 = 10.4 µg/ml) 
showed the mild anticancer activity against the Adriamycin 
(positive control) as shown in fig. 2 and fig. 3. 
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Table 4: Predicted ADMET-SAR properties of synthesized compounds 
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MA-1 0.9744 1.0000 0.5511 0.7590 0.5571 0.9967 0.7701 0.6981 0.8551 0.7045 0.9135 0.8556 0.6213 0.5884 2.3435 0.8682 
MA-2 0.9493 1.0000 0.5171 0.7313 0.5784 1.0000 0.7670 0.6377 0.8950 0.6488 0.9018 0.8979 0.5761 0.6252 2.4510 1.1856 
MA-3 0.9638 1.0000 0.5311 0.7328 0.5258 1.0000 0.7616 0.6899 0.6342 0.6601 0.9331 0.9105 0.6050 0.5773 2.4631 1.0988 
MA-4 0.9646 1.0000 0.5130 0.7314 0.5455 1.0000 0.7088 0.6572 0.9826 0.5904 0.9003 0.8952 0.6185 0.6042 2.4294 1.0799 
MA-5 0.9738 1.0000 0.5444 0.7492 0.5577 0.9882 0.7597 0.6516 0.8474 0.5498 0.9266 0.9223 0.6320 0.5720 2.3361 0.8416 
MA-6 0.9676 1.0000 0.5509 0.7640 0.5474 0.9927 0.7597 0.7382 0.8982 0.5498 0.9266 0.9173 0.6778 0.5089 2.2955 0.7848 
MA-7 0.9566 1.0000 0.5000 0.7659 0.5313 0.9927 0.6947 0.6941 0.9332 0.5292 0.9169 0.9214 0.6211 0.5279 2.4114 0.7633 
MA-8 0.6011 0.9837 0.6440 0.8815 0.5577 0.9792 0.6908 0.6325 0.9118 0.5814 0.9178 0.8879 0.5480 0.5859 2.3483 0.7288 
MA-9 0.9559 1.0000 0.5000 0.6978 0.5437 0.9605 0.5704 0.6316 0.7687 0.6950 0.9696 0.9343 0.5187 0.4758 2.3532 0.7727 
MA-10 0.9738 1.0000 0.5444 0.7492 0.5577 0.9882 0.6670 0.6887 0.8622 0.5875 0.8585 0.9223 0.6320 0.5720 2.3361 0.8416 
MA-11 0.9621 0.9954 0.5137 0.7974 0.6170 1.0000 0.7597 0.7382 0.8982 0.5498 0.9266 0.8684 0.6683 0.4508 2.3803 0.6039 
MA-12 0.9621 0.9954 0.5137 0.7974 0.6170 1.0000 0.9597 0.6155 0.9135 0.7022 0.9403 0.8684 0.6683 0.4508 2.3803 0.6039 
MA-13 0.9134 1.000 0.5641 0.7801 0.5360 0.9806 0.9597 0.6155 0.9135 0.7022 0.9403 0.8906 0.5402 0.5525 2.4074 0.9266 
MA-14 0.9141 0.9875 0.5385 0.8366 0.8212 0.9843 0.6884 0.6462 0.6942 0.7118 0.9098 0.8074 0.5853 0.4511 0.6728 0.8016 
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Further, only active compounds show significant interaction at the 
active site of receptor via hydrogen bonding to some important amino 
acids such as ASP, VAL, MET, LYS etc. Combination of different 
interactions leads to significant penetration of compounds at the active 
site of the receptor with good docking score. Hence, it is observed that 
molecular docking and anticancer activity are correlated with each 
other. The results of anticancer activity are depicted in fig. 2 and fig. 3 
respectively. 
In silico ADMET SAR study 
Pharmacokinetic and pharmacodynamic profiling of the drug is one 
of the most important and critical Parameters; beginning with the 
site of administration, absorption into the systemic circulation, 
gesticulation in blood, elimination through urine. ADMET profiling of 
the synthesized triazine derivatives has been calculated with the 
help of online software database namely admet SAR. There are 
diverse parameters for determining the permeability of the drugs 
through various body barriers such as blood-brain barrier (BBB), 
human intestinal absorption, Caco-2 cell permeation, absorption in 
the intestine, renal organic cation transport and AMES toxicity test. 
P-glycoprotein is the membrane efflux transporter which plays a 
critical role in the determination of pharmacokinetic [ADMEandT] 
profile of some therapeutic agents and in the multidrug resistance 
(MDR) phenomena. Recognition of the P-glycoprotein substrates is 
an important process in the early stage of the drug discovery. 
Cytochrome-P enzyme family (CYPs) is the essential enzyme which 
plays a critical role in detoxification of drugs and the biosynthesis of 
endogenous molecules. The direct or indirect correlation of the 
carcinogenicity of therapeutic agents with the properties of the 
molecule is an important feature in the pharmacokinetic profiling of 
the drugs. The results of carcinogenicity, mutagenicity from the 
admetSAR software have been listed in table 4. The triazine 
derivatives might be able to pass through the human intestinal 
barrier and could be absorbed from the intestine. Out of all the 
synthesized triazine derivatives, majority of the compounds do not 
show any kind of toxicity or mutagenicity. 
CONCLUSION 
A series of novel triazine derivatives were synthesized and chemical 
structure of all analogs was confirmed by IR, 1H-NMR and mass 
spectroscopy. The compounds were evaluated for anticancer activity 
using MCF-7 and K-562 cell lines. The compound MA-7, MA-8, MA-
12, MA-13 and MA-14 were found most active from the series 
against different cell lines. Further, synthesized compounds were 
docked on the crystal structure of EGFR receptor to identify the 
binding mode of interaction. Docking interaction and score supports 
triazine derivative as potent anticancer agents. Moreover, all 
compounds were subjected to in silico ADMET prediction using 
admetSAR online tool which suggest that all molecules from the 
series have appropriate ADMET properties to become a potential 
drug candidate. The results of a computational study and in vitro 
study strongly reveals that the synthesized compounds may be used 
for lead optimization for development of novel anticancer agents 
with a high degree of selectivity and specificity towards cancer cells. 
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